Letrozole Monotherapy. NCCP National SACT Regimen. HSE.

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies